Citations

Showing 10 of 108135 citations.

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation
Kanter, Julie , Bernaudin, Françoise , Bolaños‐Meade, Javier , Fitzhugh, Courtney D. , Hankins, Jane S. , Panepinto, Julie A. , Rondelli, Damiano , Shenoy, Shalini , Wagner, John E. , Woolford, Teonna, Fitzhugh, Courtney D , Hankins, Jane S , Meerpohl, Joerg J , Tisdale, John , Liem, Robert I. , Murad, M. Hassan , Walters, Mark C. , Meerpohl, Joerg J

Mayo Clinic

Blood Advances | September 28, 2021 | Volume: 5 | Issue: 18 | Pages: 3668-3689

10.1182/bloodadvances.2021004394c | PMID 34581773 Get It

Abstract Background: Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT) is currently the only curative intervention for SCD; however, guidelines are needed to inform how to apply HSCT in clinical practice. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and health professionals in their decisions about HSCT for SCD. Methods: The multidisciplinary guideline panel formed by ASH included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews (through 2019). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 8 recommendations to help patients and providers assess how individuals with SCD should consider the timing and type of HSCT. Conclusions: The evidence review yielded no randomized controlled clinical trials for HSCT in SCD; therefore, all recommendations are based on very low certainty in the evidence. Key recommendations include considering HSCT for those with neurologic injury or recurrent acute chest syndrome at an early age and to improve nonmyeloablative regimens. Future research should include the development of a robust SCD registry to serve as a comparator for HSCT studies.
Diet Effects on Cerebrospinal Fluid Amino Acids Levels in Adults with Normal Cognition and Mild Cognitive Impairment
Russin, Kate J., Montine, Thomas J. , Baker, Laura D. , Craft, Suzanne , Nair, K. Sreekumaran

Mayo Clinic

Journal of Alzheimer's Disease | September 28, 2021 | Volume: 84 | Issue: 2 | Pages: 843-853

10.3233/jad-210471 | PMID 34602470 Get It

Background: Exploration of cerebrospinal fluid (CSF) amino acids and the impact of dietary intake on central levels may provide a comprehensive understanding of the metabolic component of Alzheimer’s disease. Objective: The objective of this exploratory study was to investigate the effects of two diets with varied nutrient compositions on change in CSF amino acids levels in adults with mild cognitive impairment (MCI) and normal cognition (NC). Secondary objectives were to assess the correlations between the change in CSF amino acids and change in Alzheimer’s disease biomarkers. Methods: In a randomized, parallel, controlled feeding trial, adults (NC, n = 20; MCI, n = 29) consumed a high saturated fat (SFA)/glycemic index (GI) diet [HIGH] or a low SFA/GI diet [LOW] for 4 weeks. Lumbar punctures were performed at baseline and 4 weeks. Results: CSF valine increased and arginine decreased after the HIGH compared to the LOW diet in MCI (ps = 0.03 and 0.04). This pattern was more prominent in MCI versus NC (diet by diagnosis interaction ps = 0.05 and 0.09), as was an increase in isoleucine after the HIGH diet (p = 0.05). Changes in CSF amino acids were correlated with changes in Alzheimer’s disease CSF biomarkers Aβ42, total tau, and p-Tau 181, with distinct patterns in the relationships by diet intervention and cognitive status. Conclusion: Dietary intake affects CSF amino acid levels and the response to diet is differentially affected by cognitive status.
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids
Archer, David F. , Owens, Charlotte D., Barnhart, Kurt T. , Bradley, Linda D., Gillispie-Bell, Veronica, Imudia, Anthony N. , Liu, Ran , Stewart, Elizabeth A. , Bradley, Linda D., Feinberg, Eve C. , Kim, Jin Hee , Al‐Hendy, Ayman

Mayo Clinic

Journal of Women's Health | September 28, 2021 | Volume: 31 | Issue: 5 | Pages: 698-705

10.1089/jwh.2021.0152 | PMID 34582715 Get It

Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily) or placebo who were not considered responders in pooled analysis of two phase 3, 6-month randomized clinical trials (Elaris UF-1 and UF-2). Methods: Responders were defined as women who met both primary end point bleeding criteria (<80 mL menstrual blood loss [MBL] during the final month and ≥50% reduction in MBL from baseline to the final month) and either completed the study or discontinued due to predefined reasons. Thus, women termed nonresponders who were analyzed in this study who met neither or one bleeding end point or met both criteria but prematurely discontinued treatment because of adverse events, perceived lack of efficacy, or required surgical or interventional treatment for UFs were analyzed in this study. This post hoc analysis assessed mean changes from baseline in MBL, as well as adverse events. Results: Among 367 women receiving elagolix with add-back with observed data, 89 (24%) were not considered responders. Within this subset, 17 (19%) women met both bleeding criteria but prematurely discontinued treatment for the reasons mentioned above, while 23 (26%) met one bleeding criterion and 49 (55%) met neither bleeding criteria, regardless of discontinuation status. Among all nonresponders, a numerical trend toward greater mean reductions in MBL was observed in those receiving elagolix with add-back, compared with placebo group nonresponders. No differences in adverse events were observed between responders and nonresponders. Conclusion: Forty of 89 (45%) women with HMB and UFs who were classified as nonresponders in the UF-1 or UF-2 trials may have had a clinically meaningful response to elagolix with add-back therapy because they met at least one of the objective bleeding criteria. Clinical Trial Registration: Clinicaltrials.gov, NCT02654054 and NCT02691494. (NEJM 2020; 382:328–340) DOI: 10.1056/NEJMoa1904351
Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma
Vardam-Kaur, Trupti , Pathangey, Latha , Bergsagel, P. Leif , Cohen, Peter A. , Gendler, Sandra , Bergsagel, P. Leif , Pathangey, Latha B, McCormick, Daniel J., McCormick, Daniel

Mayo Clinic

Oncotarget | September 28, 2021 | Volume: 12 | Issue: 20 | Pages: 2051-2067

10.18632/oncotarget.28067 | PMID 34611479 Get It

Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
Force, US Preventive Services Task, Davidson, Karina W. , Mangione, Carol M. , Cabana, Michael D. , Caughey, Aaron B. , Davis, Esa M. , Donahue, Katrina E , Kubik, Martha , Ogedegbe, Gbenga, Silverstein, Michael, Stevermer, James , Tseng, Chien‐Wen , Wong, John B. , Doubeni, Chyke A. , Davidson, Karina , Force, US Preventive Services Task, Barry, Michael J. , Li, Li , Pbert, Lori A. , Simon, Melissa Andrea

Mayo Clinic

JAMA | September 28, 2021 | Volume: 326 | Issue: 12 | Pages: 1186

10.1001/jama.2021.14781 | PMID 34581729 Get It

Importance Preeclampsia is one of the most serious health problems that affect pregnant persons. It is a complication in approximately 4% of pregnancies in the US and contributes to both maternal and infant morbidity and mortality. Preeclampsia also accounts for 6% of preterm births and 19% of medically indicated preterm births in the US. There are racial and ethnic disparities in the prevalence of and mortality from preeclampsia. Non-Hispanic Black women are at greater risk for developing preeclampsia than other women and experience higher rates of maternal and infant morbidity and perinatal mortality. Objective To update its 2014 recommendation, the USPSTF commissioned a systematic review to evaluate the effectiveness of low-dose aspirin use to prevent preeclampsia. Population Pregnant persons at high risk for preeclampsia who have no prior adverse effects with or contraindications to low-dose aspirin. Evidence Assessment The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia. Recommendation The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication for preeclampsia after 12 weeks of gestation in persons who are at high risk for preeclampsia. (B recommendation)
Biomarkers for prognosis in pancreatic neuroendocrine tumors
Zhu, Mojun , Sorenson, K, Sorenson, Karl R, Liu, Rebecca H. , Gould Rothberg, Bonnie E , Hálfdánarson, Þorvarður R.

Mayo Clinic

Endocrine-Related Cancer | September 28, 2021 | Volume: 28 | Issue: 12 | Pages: 773-782

10.1530/erc-21-0075 | PMID 34582360 Get It

Pancreatic neuroendocrine tumors (PNETs) encompass a diverse group of malignancies marked by histological heterogeneity and highly variable clinical outcomes. We performed a systematic review on potential prognostic biomarkers in PNETs by searching the PubMed database. A total of 472 manuscripts were reviewed in detail, of which 52 multivariate studies met the inclusion criteria proposed by the Reporting Recommendations for Tumor Marker Prognostic Studies. These altogether analyzed 53 unique targets, and 36 of them were statistically associated with survival.
PD-1 inhibition in advanced myeloproliferative neoplasms
Hobbs, Gabriela , Bozkus, Cansu Cimen , Moshier, Erin , Dougherty, Mikaela , Bar‐Natan, Michal , Sandy, Lonette, Johnson, Kathryn, Foster, Julia, Som, Tina T., Marble, Hetal D. , Salama, Mohamed E. , Zubizarreta, Nicole , Wadleigh, Martha , Stone, Richard M. , Iancu‐Rubin, Camelia , Cimen Bozkus, Cansu , Marble, Hetal , Salama, Mohamed , Iancu-Rubin, Camelia , Mascarenhas, John , Hobbs, Gabriela S , Macrae, Molly, Jamal, Siraj M. El , Bhardwaj, Nina , Mascarenhas, John

Mayo Clinic

Blood Advances | September 28, 2021 | Volume: 5 | Issue: 23 | Pages: 5086-5097

10.1182/bloodadvances.2021005491 | PMID 34581778 Get It

Abstract Myelofibrosis (MF) is a clonal stem cell neoplasm characterized by abnormal JAK-STAT signaling, chronic inflammation, cytopenias, and risk of transformation to acute leukemia. Despite improvements in the therapeutic options for patients with MF, allogeneic hematopoietic stem cell transplantation remains the only curative treatment. We previously demonstrated multiple immunosuppressive mechanisms in patients with MF, including increased expression of programmed cell death protein 1 (PD-1) on T cells compared with healthy controls. Therefore, we conducted a multicenter, open-label, phase 2, single-arm study of pembrolizumab in patients with Dynamic International Prognostic Scoring System category of intermediate-2 or greater primary, post-essential thrombocythemia or post-polycythemia vera myelofibrosis that were ineligible for or were previously treated with ruxolitinib. The study followed a Simon 2-stage design and enrolled a total of 10 patients, 5 of whom had JAK2V617mutation, 2 had CALR mutation, and 6 had additional mutations. Most patients were previously treated with ruxolitinib. Pembrolizumab treatment was well tolerated, but there were no objective clinical responses, so the study closed after the first stage was completed. However, immune profiling by flow cytometry, T-cell receptor sequencing, and plasma proteomics demonstrated changes in the immune milieu of patients, which suggested improved T-cell responses that can potentially favor antitumor immunity. The fact that these changes were not reflected in a clinical response strongly suggests that combination immunotherapeutic approaches rather than monotherapy may be necessary to reverse the multifactorial mechanisms of immune suppression in myeloproliferative neoplasms. This trial was registered at www.clinicaltrials.gov as #NCT03065400.
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation
Riedell, Peter A. , Hamadani, Mehdi , Ahn, Kwang Woo , Litovich, Carlos, Brunstein, Claudio G. , Cashen, Amanda F. , Cohen, Jonathon B. , Epperla, Narendranath , Hill, Brian T. , Im, Annie , Inwards, David J. , Lister, John , McCarty, John M. , Pingali, Sai Ravi , Shaughnessy, Paul , Solh, Melhem , Stiff, Patrick J. , Kharfan‐Dabaja, Mohamed A. , Herrera, Alex F. , Sauter, Craig S. , Smith, Sonali M. , Kharfan-Dabaja, Mohamed A , Herrera, Alex F , Hamadani, Mehdi , Epperla, Narendranath , Riedell, Peter A , Hill, Brian , Shadman, Mazyar , Vose, Julie M.

Mayo Clinic

British Journal of Haematology | September 28, 2021 | Volume: 195 | Issue: 5 | Pages: 757-763

10.1111/bjh.17865 | PMID 34581433 Get It

SummaryIn young and fit patients with mantle cell lymphoma (MCL), intensive induction therapy followed by a consolidative autologous haematopoietic cell transplant (autoHCT) is the standard of care in the front‐line setting. Recently, time‐to‐event analysis has emerged as an important risk assessment tool in lymphoma, though its impact in MCL is not well defined. We utilized the Center for International Blood and Marrow Transplant Research database to evaluate the effect of post‐autoHCT time to relapse on overall survival (OS) over time in 461 patients who underwent autoHCT within 12 months of MCL diagnosis. On multivariate analysis, the impact of relapse on OS was greatest at the six‐month [hazard ratio (HR) = 7·68], 12‐month (HR = 6·68), and 18‐month (HR = 5·81) landmark timepoints. Using a dynamic landmark model we demonstrate that adjusted OS at five years following each landmark timepoint improved with time for relapsing and non‐relapsing patients. Furthermore, early relapse (<18 months) following autoHCT defines a high‐risk group with inferior post‐relapse OS. This retrospective analysis highlights the impact of time to relapse on OS in MCL patients undergoing up‐front autoHCT and emphasizes the need to consider novel therapeutic approaches for patients suffering early relapse.
Increasing utility of Google Trends in monitoring cardiovascular disease
Senecal, Conor , Mahowald, Madeline , Lerman, Lilach O. , Lopes-Jimenez, Francisco, Lerman, Lilach, Mahowald, Madeline K , Lerman, Amir

Mayo Clinic

DIGITAL HEALTH | September 28, 2021 | Volume: 7 | Issue: No issue available | Pages: No page available

10.1177/20552076211033420 | PMID 34873449 Get It

Introduction Cardiovascular disease is the most common cause of morbidity and mortality in the United States. Patients are increasingly using internet search to find health-related information, including searches for cardiovascular diseases and risk factors. We sought to evaluate the change in the state by state correlation of cardiovascular disease and risk factors with Google Trends search volumes. Methods Data on cardiovascular disease hospitalizations and risk factor prevalence were obtained from the publically available Centers for Disease Control and Prevention website from 2006 to 2018. Google Trends data were obtained for matching conditions and time periods. Simple linear regression was performed to evaluate for an increase in correlation over time. Results Hospitalizations for six separate cardiovascular disease conditions showed moderate to strong correlation with online search data in the last period studied (heart failure (0.58, p < .001), atrial fibrillation (0.57, p < .001), coronary heart disease (0.58, p < .001), myocardial infarction (0.70, p < .001), stroke (0.62, p < .001), cardiac dysrhythmia (0.46, p < .001)) in the United States. All diseases studied showed a positive increase in correlation throughout the time period studied ( p < .05). All five of the cardiovascular risk factors studied showed strong correlation with online search data; diabetes ( R = 0.78, p < .001), cigarette use ( R = 0.79, p < .001), hypertension ( R = 0.81, p < .001), high cholesterol ( R = 0.59, p < .001), and obesity ( p = 0.80, p < .001) in the United States. Three of the five risk factors showed an increasing correlation over time. Conclusion The prevalence of and hospitalizations for cardiovascular conditions in the United States strongly correlate with online search volumes in the United States when analyzed by state. This relationship has progressively strengthened or been strong and stable over recent years for these conditions. Google Trends represents an increasingly valuable tool for evaluating the burden of cardiovascular disease and risk factors in the United States.
Cancer Risk in Patients With Fuchs Endothelial Corneal Dystrophy
Xu, Timothy T. , Baratz, Keith H. , Fautsch, Michael P. , Hodge, David O. , Mahr, Michael A.

Mayo Clinic

Cornea | September 28, 2021 | Volume: 41 | Issue: 9 | Pages: 1088-1093

10.1097/ico.0000000000002864 | PMID 35588167 Get It

Purpose: The purpose of this study is to quantify cancer risk in patients with Fuchs endothelial corneal dystrophy (FECD). Methods: Using the 2014 to 2016 Medicare Limited 5% Data Sets—Carrier Line File, US Medicare fee-for-service beneficiaries (aged 65 years or older) with FECD and cancer were identified through International Classification of Diseases, ninth and 10th Revision diagnostic codes from January 1, 2014, to December 31, 2016. The main outcome measures were odds ratios (ORs) of cancer at various anatomic locations in patients with versus without FECD. Results: Of the 1,462,740 Medicare beneficiaries, 15,534 patients (1.1%) had an International Classification of Disease code for FECD. Compared with US Medicare beneficiaries without FECD, patients with FECD were at increased risk for the following malignancies: breast [OR: 1.32; 95% confidence interval (CI): 1.22–1.43; P < 0.001], cutaneous basal cell (OR: 1.42; 95% CI: 1.35–1.49; P < 0.001), cutaneous melanoma (OR: 1.20; 95% CI: 1.03–1.40; P = 0.02), cutaneous squamous cell (OR: 1.45; 95% CI: 1.38–1.53; P < 0.001), ovarian (OR: 1.84; 95% CI: 1.48–2.30; P < 0.001), and thyroid (OR: 1.32; 95% CI: 1.04–1.68; P = 0.02). By contrast, FECD cases were at lower odds of having lung (OR: 0.81; 95% CI: 0.71–0.93; P = 0.003) and prostate cancer diagnoses (OR: 0.88; 95% CI: 0.81–0.96; P = 0.002). Conclusions: Patients with FECD aged 65 years or older may be at increased risk for cancer at several anatomic locations. Follow-up studies are needed to further explore the association of FECD and malignancy, elucidate potential disease mechanisms, and identify genetic and/or environmental risk factors.